PolyPid Strikes Azurity Commercialization Deal for D-PLEX100 in U.S. and Canada
I'm LongbridgeAI, I can summarize articles.PolyPid entered an exclusive license and supply agreement with Azurity Pharmaceuticals to commercialize D-PLEX100 in the U.S. and Canada for preventing surgical site infections. The deal includes $15 million upfront, potential near-term and additional milestones totaling up to $315 million, and tiered royalties. PolyPid retains rights outside North America and will manufacture the product. This partnership follows positive Phase 3 trial data and aims to strengthen PolyPid's financial position.
An update from PolyPid ( (PYPD) ) is now available.
On July 17, 2026, PolyPid entered into an exclusive license and supply agreement with Azurity Pharmaceuticals for commercialization of D-PLEX100 in the U.S. and Canada for the prevention of surgical site infections. The deal includes $15 million upfront, a $15 million near-term milestone linked to FDA NDA acceptance, potential additional milestone payments of about $300 million, and tiered royalties, while PolyPid retains rights outside North America and will manufacture and supply the product.
The partnership, announced on July 21, 2026, follows strong Phase 3 SHIELD II trial data for D-PLEX100 and marks PolyPid’s shift toward becoming a commercial-stage company. By leveraging Azurity’s specialized commercial model and funding for possible label expansions beyond abdominal indications, the collaboration is set to strengthen PolyPid’s financial position, validate its Kynatrix technology platform, and enhance its competitive standing in infection prevention therapies.
The most recent analyst rating on (PYPD) stock is a Buy
with a $9.00 price target.
To see the full list of analyst forecasts on PolyPid stock,
see the PYPD Stock Forecast page.
Spark’s Take on PYPD Stock
According to Spark, TipRanks’ AI Analyst, PYPD is a Neutral.
The score is held back primarily by weak financial fundamentals (no revenue, continued losses/cash burn, and financing risk). Offsetting this is a favorable earnings-call outlook with clear regulatory timelines and commercial readiness progress, while technicals show an uptrend but appear overbought. Valuation is difficult to anchor given negative earnings and no dividend.
To see Spark’s full report on PYPD stock,
click here.
More about PolyPid
PolyPid Ltd., based in Petach Tikva, Israel, is an innovative biopharmaceutical company focused on long-acting, controlled-release drugs that deliver therapy directly at the site of care. Its lead product, D-PLEX100, targets prevention of surgical site infections and has shown positive Phase 3 SHIELD II results, with a diverse pipeline spanning surgical care and metabolic diseases.
Average Trading Volume: 152,847
Technical Sentiment Signal: Hold
Current Market Cap: $102.5M
For an in-depth examination of PYPD stock, go to TipRanks’ Overview page.